Evaluation of degradation pathways for plasmid DNA in pharmaceutical formulations via accelerated stability studies. 2000

R K Evans, and Z Xu, and K E Bohannon, and B Wang, and M W Bruner, and D B Volkin
Department of Vaccine Pharmaceutical Research, Merck Research Laboratories, WP78-302, Sumneytown Pike, West Point, PA 19486, USA. robert_evans@merck.com

The stability of highly purified supercoiled plasmid DNA formulated in simple phosphate or Tris-buffered saline solutions has been characterized to establish the overall degradation processes that occur during storage in aqueous solution. Plasmid DNA stability was monitored during accelerated stability studies (at 50 degrees C) by measurements of supercoiled, open-circle, and linear DNA content, as well as the accumulation of apurinic sites and 8-hydroxydeoxyguanosine residues over time. The effects of formulation pH, demetalation, metal ion chelators, and ethanol (hydroxyl radical scavenger) on the supercoiled content of plasmid DNA during storage at 50 degrees C were also determined. The results indicate that free radical oxidation may be a major degradative process for plasmid DNA in pharmaceutical formulations unless specific measures are taken to control it by the addition of free radical scavengers, specific metal ion chelators, or both. The generation of hydroxyl radicals in phosphate-buffered saline was confirmed by examining the hydroxylation of phenylalanine over time by reverse phase high-performance liquid chromatography. Ethanol was found to enhance plasmid DNA stability and to inhibit the hydroxylation of phenylalanine; both observations are consistent with the known ability of ethanol to serve as a hydroxyl radical scavenger. Moreover, the combination of ethylenediamine tetraacetic acid (EDTA) and ethanol had a synergistic enhancing effect on DNA stability. However, the metal ion chelator diethylenetriaminepentaacetic acid (DTPA) was as potent as the combination of EDTA and ethanol for enhancing the stability of plasmid DNA. By controlling free radical oxidation with EDTA and ethanol, the rate constants of plasmid DNA degradation by means of depurination and beta-elimination were then determined, allowing accurate predictions of DNA storage stability as a function of formulation pH and temperature. The ability to predict plasmid DNA storage stability in the absence of free radical oxidation should prove to be a valuable tool for the design of stable pharmaceutical formulations of plasmid DNA.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008670 Metals Electropositive chemical elements characterized by ductility, malleability, luster, and conductance of heat and electricity. They can replace the hydrogen of an acid and form bases with hydroxyl radicals. (Grant & Hackh's Chemical Dictionary, 5th ed) Metal
D010084 Oxidation-Reduction A chemical reaction in which an electron is transferred from one molecule to another. The electron-donating molecule is the reducing agent or reductant; the electron-accepting molecule is the oxidizing agent or oxidant. Reducing and oxidizing agents function as conjugate reductant-oxidant pairs or redox pairs (Lehninger, Principles of Biochemistry, 1982, p471). Redox,Oxidation Reduction
D010649 Phenylalanine An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE. Endorphenyl,L-Phenylalanine,Phenylalanine, L-Isomer,L-Isomer Phenylalanine,Phenylalanine, L Isomer
D010710 Phosphates Inorganic salts of phosphoric acid. Inorganic Phosphate,Phosphates, Inorganic,Inorganic Phosphates,Orthophosphate,Phosphate,Phosphate, Inorganic
D010957 Plasmids Extrachromosomal, usually CIRCULAR DNA molecules that are self-replicating and transferable from one organism to another. They are found in a variety of bacterial, archaeal, fungal, algal, and plant species. They are used in GENETIC ENGINEERING as CLONING VECTORS. Episomes,Episome,Plasmid
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D002021 Buffers A chemical system that functions to control the levels of specific ions in solution. When the level of hydrogen ion in solution is controlled the system is called a pH buffer. Buffer
D003849 Deoxyguanosine A nucleoside consisting of the base guanine and the sugar deoxyribose.
D004270 DNA, Circular Any of the covalently closed DNA molecules found in bacteria, many viruses, mitochondria, plastids, and plasmids. Small, polydisperse circular DNA's have also been observed in a number of eukaryotic organisms and are suggested to have homology with chromosomal DNA and the capacity to be inserted into, and excised from, chromosomal DNA. It is a fragment of DNA formed by a process of looping out and deletion, containing a constant region of the mu heavy chain and the 3'-part of the mu switch region. Circular DNA is a normal product of rearrangement among gene segments encoding the variable regions of immunoglobulin light and heavy chains, as well as the T-cell receptor. (Riger et al., Glossary of Genetics, 5th ed & Segen, Dictionary of Modern Medicine, 1992) Circular DNA,Circular DNAs,DNAs, Circular

Related Publications

R K Evans, and Z Xu, and K E Bohannon, and B Wang, and M W Bruner, and D B Volkin
April 2009, Journal of pharmaceutical sciences,
R K Evans, and Z Xu, and K E Bohannon, and B Wang, and M W Bruner, and D B Volkin
June 1998, Journal of pharmaceutical sciences,
R K Evans, and Z Xu, and K E Bohannon, and B Wang, and M W Bruner, and D B Volkin
January 2000, Developments in biologicals,
R K Evans, and Z Xu, and K E Bohannon, and B Wang, and M W Bruner, and D B Volkin
March 2013, Acta pharmaceutica (Zagreb, Croatia),
R K Evans, and Z Xu, and K E Bohannon, and B Wang, and M W Bruner, and D B Volkin
January 1969, Bulletin of the Parenteral Drug Association,
R K Evans, and Z Xu, and K E Bohannon, and B Wang, and M W Bruner, and D B Volkin
January 2007, Biotechnology annual review,
R K Evans, and Z Xu, and K E Bohannon, and B Wang, and M W Bruner, and D B Volkin
February 2019, Journal of pharmaceutical and biomedical analysis,
R K Evans, and Z Xu, and K E Bohannon, and B Wang, and M W Bruner, and D B Volkin
October 1972, Journal of pharmaceutical sciences,
R K Evans, and Z Xu, and K E Bohannon, and B Wang, and M W Bruner, and D B Volkin
March 2011, Journal of pharmaceutical sciences,
R K Evans, and Z Xu, and K E Bohannon, and B Wang, and M W Bruner, and D B Volkin
July 2012, Journal of pharmaceutical sciences,
Copied contents to your clipboard!